NASDAQ:CRVO CervoMed Q1 2026 Earnings Results & Report $3.22 -0.06 (-1.83%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$3.25 +0.03 (+1.02%) As of 10/9/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CervoMed beat analyst earnings expectations in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$0.86 versus the -$0.90 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 15, 2026TimeBefore Market OpensConference Call7:00 AM ET CervoMed EPS ResultsActual EPS-$0.86Consensus EPS -$0.90Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCervoMed Revenue ResultsActual RevenueN/AExpected Revenue$0.07 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCervoMed's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CervoMed Q1 2026 Earnings FAQ Did CervoMed beat earnings estimates for Q1 2026? CervoMed (NASDAQ:CRVO) reported earnings of -$0.86 per share for Q1 2026, beating the consensus estimate of -$0.90. The report was announced on Friday, May 15, 2026. When is CervoMed's next earnings date? CervoMed's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for CervoMed on the company's earnings history page. CervoMed Earnings HeadlinesCervoMed's (CRVO) Buy Rating Reiterated at HC WainwrightOctober 5, 2026 | americanbankingnews.comCervoMed Inc. (NASDAQ:CRVO) Stock Now Rated "Moderate Buy" by Wall Street AnalystsOctober 3, 2026 | americanbankingnews.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared. | Stansberry Research (Ad)CervoMed Advances Neflamapimod With New Tablet Formulation And FDA Dose FlexibilitySeptember 28, 2026 | rttnews.comCervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure LimitSeptember 28, 2026 | globenewswire.comCervoMed Inc. to Participate in Panel Discussion and One-on-One Meetings at 5th Annual ROTH Healthcare Opportunities ConferenceSeptember 22, 2026 | quiverquant.comQSee More CervoMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email. Email Address About CervoMedCervoMed (NASDAQ:CRVO) (NASDAQ: CRVO) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research programs are aimed at addressing conditions involving cognitive impairment and other neurological dysfunction. CervoMed’s lead investigational product is neflamapimod, an orally administered, selective inhibitor of the p38 alpha enzyme. The company is evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurodegenerative disorder associated with cognitive, behavioral and movement-related symptoms. The compound has also been studied in other forms of dementia, including Alzheimer’s disease. The company was formed through the combination of EIP Pharma and Diffusion Pharmaceuticals and adopted the CervoMed name in 2023. Its development activities are primarily centered on clinical research and trials in the United States. CervoMed does not currently market an approved commercial product.View CervoMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
